Cargando…
Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation
Multiple animal and human studies have shown that administration of GLP-1RA can enhance β-cell recovery, reduce insulin dosage, reduce HbA1c content in the blood, reduce the risk of hypoglycemia and reduce inflammation. In the NOD mouse model, peptide VP treatment can prevent and treat type 1 diabet...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878925/ https://www.ncbi.nlm.nih.gov/pubmed/33574570 http://dx.doi.org/10.1038/s41598-021-83201-4 |
_version_ | 1783650425068584960 |
---|---|
author | Gao, Huashan Zhao, Qian Tang, Shanshan Li, Kaiying Qin, Fujian Song, Ziwei Pan, Yi Jin, Liang Zhang, Yanfeng |
author_facet | Gao, Huashan Zhao, Qian Tang, Shanshan Li, Kaiying Qin, Fujian Song, Ziwei Pan, Yi Jin, Liang Zhang, Yanfeng |
author_sort | Gao, Huashan |
collection | PubMed |
description | Multiple animal and human studies have shown that administration of GLP-1RA can enhance β-cell recovery, reduce insulin dosage, reduce HbA1c content in the blood, reduce the risk of hypoglycemia and reduce inflammation. In the NOD mouse model, peptide VP treatment can prevent and treat type 1 diabetes through immunomodulation. Therefore, we designed a new dual-functional PGLP-1-VP, which is expected to combine the anti-inflammatory effect of PGLP-1 and the immunomodulatory effect of VP peptide. In streptozotocin-induced hyperglycemic mice model, we demonstrated that PGLP-1-VP can act as a GLP-1R agonist to improve hyperglycemia and increase insulin sensitivity. In the NOD mouse model, PGLP-1-VP treatment reduced morbidity, mortality, and pancreatic inflammation, and showed superior effect to PGLP-1 or VP treatment alone, confirming that PGLP-1-VP may act as a dual-function peptide. PGLP-1-VP provided immunomodulatory effect through increasing Th2 cell percentage and balancing the ratio of Th2/Th1 in spleen and PLN, similar to P277 and VP. Additionally, PGLP-1-VP and PGLP-1 act the anti-inflammation by increasing Treg cells and TGF-β1 content like DPP-IV inhibitor. Taken together, our data shows that the dual-functional PGLP-1-VP reduces morbidity and mortality in the NOD model, suggesting a potential role in preventing and treating type 1 diabetes. |
format | Online Article Text |
id | pubmed-7878925 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-78789252021-02-12 Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation Gao, Huashan Zhao, Qian Tang, Shanshan Li, Kaiying Qin, Fujian Song, Ziwei Pan, Yi Jin, Liang Zhang, Yanfeng Sci Rep Article Multiple animal and human studies have shown that administration of GLP-1RA can enhance β-cell recovery, reduce insulin dosage, reduce HbA1c content in the blood, reduce the risk of hypoglycemia and reduce inflammation. In the NOD mouse model, peptide VP treatment can prevent and treat type 1 diabetes through immunomodulation. Therefore, we designed a new dual-functional PGLP-1-VP, which is expected to combine the anti-inflammatory effect of PGLP-1 and the immunomodulatory effect of VP peptide. In streptozotocin-induced hyperglycemic mice model, we demonstrated that PGLP-1-VP can act as a GLP-1R agonist to improve hyperglycemia and increase insulin sensitivity. In the NOD mouse model, PGLP-1-VP treatment reduced morbidity, mortality, and pancreatic inflammation, and showed superior effect to PGLP-1 or VP treatment alone, confirming that PGLP-1-VP may act as a dual-function peptide. PGLP-1-VP provided immunomodulatory effect through increasing Th2 cell percentage and balancing the ratio of Th2/Th1 in spleen and PLN, similar to P277 and VP. Additionally, PGLP-1-VP and PGLP-1 act the anti-inflammation by increasing Treg cells and TGF-β1 content like DPP-IV inhibitor. Taken together, our data shows that the dual-functional PGLP-1-VP reduces morbidity and mortality in the NOD model, suggesting a potential role in preventing and treating type 1 diabetes. Nature Publishing Group UK 2021-02-11 /pmc/articles/PMC7878925/ /pubmed/33574570 http://dx.doi.org/10.1038/s41598-021-83201-4 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Gao, Huashan Zhao, Qian Tang, Shanshan Li, Kaiying Qin, Fujian Song, Ziwei Pan, Yi Jin, Liang Zhang, Yanfeng Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation |
title | Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation |
title_full | Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation |
title_fullStr | Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation |
title_full_unstemmed | Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation |
title_short | Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation |
title_sort | continuous stimulation of dual-function peptide pglp-1-vp inhibits the morbidity and mortality of nod mice through anti-inflammation and immunoregulation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878925/ https://www.ncbi.nlm.nih.gov/pubmed/33574570 http://dx.doi.org/10.1038/s41598-021-83201-4 |
work_keys_str_mv | AT gaohuashan continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation AT zhaoqian continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation AT tangshanshan continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation AT likaiying continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation AT qinfujian continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation AT songziwei continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation AT panyi continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation AT jinliang continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation AT zhangyanfeng continuousstimulationofdualfunctionpeptidepglp1vpinhibitsthemorbidityandmortalityofnodmicethroughantiinflammationandimmunoregulation |